ESR1 and cancer: Such downregulation is a well-established mechanism of acquired resistance, as seen with reduced folate carrier expression or impaired polyglutamylation in methotrexate resistance (35), loss of estrogen receptor levels in tamoxifen-treated cancers (36), and decreased epidermal growth factor receptor expression following epidermal growth factor receptor inhibitor therapy (37).